Mismatch repair deficiency and response to immune checkpoint blockade

Oncologist

Volumn 21, Issue 10, 2016, Pages 1200-1211

  Lee, Valerie ^a   Murphy, Adrian ^a   Le, Dung T ^a   Diaz, Luis A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Colonic neoplasms; Colorectal neoplasms; DNA mismatch repair; Hereditary nonpolyposis; Immunotherapy; Microsatellite instability

Indexed keywords

PROGRAMMED DEATH 1 RECEPTOR;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; COLON CANCER; ENDOMETRIUM CANCER; GENE SEQUENCE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; OVARY CANCER; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; ANTAGONISTS AND INHIBITORS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS;

DNA MISMATCH REPAIR; HUMANS; IMMUNOTHERAPY; MICROSATELLITE INSTABILITY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84991735355     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0046     Document Type: Review

References (181)

1. Le DT, Uram JN, Wang H. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-2520.
2. Lynch HT, Snyder CL, Shaw TG et al. Milestones of Lynch syndrome: 1895-2015. Nat Rev Cancer 2015;15:181-194.
3. Boland CR, Lynch HT. The history of Lynch syndrome. Fam Cancer 2013;12:145-157.
4. Aaltonen LA, Peltomäki P, Leach FS et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812-816.
5. Ionov Y, Peinado MA, Malkhosyan S et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993;363:558-561.
6. Peltomäki P, Aaltonen LA, Sistonen P et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science 1993;260:810-812.
7. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-819.
8. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138: 2073-2087.
9. Fishel R, Lescoe MK, Rao MR et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75:1027-1038.
10. Leach FS, Nicolaides NC, Papadopoulos N et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75: 1215-1225.
11. Parsons R, Li GM, Longley MJ. et al. Hypermutability and mismatch repair deficiency in RER1 tumor cells. Cell 1993;75:1227-1236.
12. Lindblom A, Tannergård P, Werelius B et al. Genetic mapping of a second locus predisposing to hereditary non-polyposis colon cancer. Nat Genet 1993;5:279-282.
13. Bronner CE, Baker SM, Morrison PT et al. MutationintheDNAmismatchrepairgenehomologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994;368:258-261.
14. Papadopoulos N, Nicolaides NC, Wei YF et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994;263:1625-1629.
15. Nicolaides NC, Papadopoulos N, Liu B et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994;371:75-80.
16. da Costa LT, Liu B, El-Deiry W et al. Polymerase delta variants in RER colorectal tumours. Nat Genet 1995;9:10-11.
17. Palombo F, Gallinari P, Iaccarino I et al. GTBP, a 160-kilodaltonproteinessential formismatch-binding activity in human cells. Science 1995;268: 1912-1914.
18. Papadopoulos N, Nicolaides NC, Liu B et al. Mutations of GTBP in genetically unstable cells. Science 1995;268:1915-1917.
19. Miyaki M, Konishi M, Tanaka K et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997; 17:271-272.
20. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-337.
21. Suraweera N, Duval A, Reperant M et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 2002;123: 1804-1811.
22. Woerner SM, Benner A, Sutter C et al. Pathogenesis of DNA repair-deficient cancers: a statistical meta-analysis of putative real common target genes. Oncogene 2003;22:2226-2235.
23. Kohlmann W, Gruber SB. Lynch syndrome. In: Pagon RA, Adam MP, Ardinger HH et al, eds. Gene Reviews. Seattle, WA: University of Washington, Seattle; 1993.
24. Peltomäki P, Vasen H. Mutations associated with HNPCC predisposition—Update of ICG-HNPCC/ INSiGHT mutation database. Dis Markers 2004;20: 269-276.
25. Woods MO, Williams P, Careen A et al. A new variant database for mismatch repair genes associated with Lynch syndrome. Hum Mutat 2007;28: 669-673.
26. Ligtenberg MJ, Kuiper RP, Chan TL et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 39 exons of TACSTD1. Nat Genet 2009;41:112-117.
27. Yamamoto H, Imai K. Microsatellite instability: An update. Arch Toxicol 2015;89:899-921.
28. Valeri N, Gasparini P, Fabbri M et al. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci USA 2010;107: 6982-6987.
29. Valeri N, Gasparini P, Braconi C et al. MicroRNA-21 induces resistance to 5-fluorouracil by downregulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci USA 2010;107:21098-21103.
30. Wu Y, Berends MJ, Mensink RG et al. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet 1999;65:1291-1298.
31. Carethers JM, Stoffel EM. Lynch syndromeand Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer. World J Gastroenterol 2015;21:9253-9261.
32. Perucho M. Correspondence re: C.R. Boland et al., A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res., 58: 5248-5257, 1998. Cancer Res 1999;59: 249-256.
33. Laiho P, Launonen V, Lahermo P et al. Low-level microsatellite instability in most colorectal carcinomas. Cancer Res 2002;62:1166-1170.
34. Wu CW, Chen GD, Jiang KC et al. A genomewide study of microsatellite instability in advanced gastric carcinoma. Cancer 2001;92:92-101.
35. Kim TM, Laird PW, Park PJ. The landscape of microsatellite instability in colorectal and endometrial cancer genomes. Cell 2013;155:858-868.
36. Carethers JM, Koi M, Tseng-Rogenski SS. EMAST is a form of microsatellite instability that is initiated by inflammation and modulates colorectal cancer progression. Genes (Basel) 2015;6:185-205.
37. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 2008;10: 293-300.
38. Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J Mol Diagn 2008; 10:301-307.
39. Umar A, Boland CR, Terdiman JP et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96: 261-268.
40. Sood AK, Holmes R, Hendrix MJ et al. Application of the National Cancer Institute international criteria for determination of microsatellite instability in ovarian cancer. Cancer Res 2001;61: 4371-4374.
41. Laghi L, Bianchi P, Malesci A. Differences and evolution of the methods for the assessment of microsatellite instability. Oncogene 2008;27: 6313-6321.
42. McConechy MK, Talhouk A, Li-Chang HH et al. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. Gynecol Oncol 2015;137:306-310.
43. Bartley AN, Luthra R, Saraiya DS et al. Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing. Cancer Prev Res (Phila) 2012;5:320-327.
44. Zhang X, Li J. Era of universal testing of microsatellite instability in colorectal cancer. World J Gastrointest Oncol 2013;5:12-19.
45. Tafe LJ. Targeted next-generation sequencing for hereditary cancer syndromes: A focus on Lynch syndrome and associated endometrial cancer. J Mol Diagn 2015;17:472-482.
46. Stadler ZK, Battaglin F, Middha S et al. Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in nextgeneration sequencing panels. J Clin Oncol 2016;34: 2141-2147.
47. Salipante SJ, Scroggins SM, Hampel HL et al. Microsatellite instability detection by next generation sequencing. Clin Chem 2014;60:1192-1199.
48. Vasen HF, Watson P, Mecklin JP et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453-1456.
49. National Comprehensive Cancer Network. NCCN Guidelines: Colon Cancer, Version 2.2016. Available at https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed April 2, 2016.
50. Heald B, Plesec T, Liu X et al. Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J Clin Oncol 2013;31:1336-1340.
51. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513: 202-209.
52. Corso G, Velho S, Paredes J et al. Oncogenic mutations in gastric cancer with microsatellite instability. Eur J Cancer 2011;47:443-451.
53. Zhu L, Li Z, Wang Y et al. Microsatellite instability and survival in gastric cancer: A systematic review and meta-analysis. Mol Clin Oncol 2015;3:699-705.
54. Czopek J, Bialas M, Rudzki Z et al. The relationship between gastric cancer cells circulating in the blood and microsatellite instability positive gastric carcinomas. Aliment Pharmacol Ther 2002; 16(Suppl 2):128-136.
55. Oki E, Kakeji Y, Zhao Y et al. Chemosensitivity and survival in gastric cancer patients with microsatellite instability. Ann Surg Oncol 2009;16: 2510-2515.
56. Seo JY, Jin EH, Jo HJ et al. Clinicopathologic and molecular features associated with patient age in gastric cancer. World J Gastroenterol 2015;21: 6905-6913.
57. Kim SY, Choi YY, An JY et al. The benefit of microsatellite instability is attenuated by chemotherapy in stage IIand stage III gastric cancer: Results from a large cohort with subgroup analyses. Int J Cancer 2015;137:819-825.
58. Williams AS, Huang WY. The analysis of microsatellite instability in extracolonic gastrointestinal malignancy. Pathology 2013;45:540-552.
59. Rodríguez-Hernández I, Garcia JL, Santos-Briz A et al. Integrated analysis of mismatch repair system in malignant astrocytomas. PLoS One 2013; 8:e76401.
60. Viana-Pereira M, Lee A, Popov S et al. Microsatellite instability in pediatric high grade glioma is associated with genomic profile and differential target gene inactivation. PLoS One 2011;6:e20588.
61. Pollack IF, Hamilton RL, Sobol RW et al. Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: A report from the Children’s Oncology Group. Pediatr Blood Cancer 2010;55:1066-1071.
62. Viana-Pereira M, Almeida I, Sousa S et al. Analysis of microsatellite instability in medulloblastoma. Neuro-oncol 2009;11:458-467.
63. Maxwell JA, Johnson SP, McLendon RE et al. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res 2008;14:4859-4868.
64. Vladimirova V, Denkhaus D, Soerensen N et al. Low level of microsatellite instability in paediatric malignant astrocytomas. Neuropathol Appl Neurobiol 2008;34:547-554.
65. Eckert A, Kloor M, Giersch A et al. Microsatellite instability in pediatric and adult high-grade gliomas. Brain Pathol 2007;17:146-150.
66. Martinez R, Schackert HK, Appelt H et al. Lowlevel microsatellite instability phenotype in sporadic glioblastoma multiforme. J Cancer Res Clin Oncol 2005;131:87-93.
67. Alonso M, Hamelin R, Kim M et al. Microsatellite instability occurs in distinct subtypes of pediatric but not adult central nervous system tumors. Cancer Res 2001;61:2124-2128.
68. Leung SY, Chan TL, Chung LP et al. Microsatellite instability and mutation of DNA mismatch repair genes in gliomas. Am J Pathol 1998;153: 1181-1188.
69. Siah SP, Quinn DM, Bennett GD et al. Microsatellite instability markers in breast cancer: A review and study showing MSI was not detected at ‘BAT 25’and ‘BAT26’microsatellitemarkers in earlyonset breast cancer. Breast Cancer Res Treat 2000; 60:135-142.
70. Sarrió D, Moreno-Bueno G, Hardisson D et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: Relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer 2003;106: 208-215.
71. Wen YH, Brogi E, Zeng Z et al. DNA mismatch repair deficiency in breast carcinoma: A pilot study of triple-negative and non-triple-negative tumors. Am J Surg Pathol 2012;36:1700-1708.
72. Lacroix-Triki M, Lambros MB, Geyer FC et al. Absence of microsatellite instability in mucinous carcinomas of the breast. Int J Clin Exp Pathol 2010; 4:22-31.
73. Adem C, Soderberg CL, Cunningham JM et al. Microsatellite instability in hereditary and sporadic breast cancers. Int J Cancer 2003;107:580-582.
74. Seitz S, Wassmuth P, Plaschke J et al. Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines. Genes Chromosomes Cancer 2003;37:29-35.
75. Demokan S, Muslumanoglu M, Yazici H et al. Investigation of microsatellite instability in Turkish breast cancer patients. Pathol Oncol Res 2002;8: 138-141.
76. Huang HN, Lin MC, Tseng LH et al. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression. Histopathology 2015;66:517-528.
77. Shilpa V, Bhagat R, Premalata CS et al. Microsatellite instability, promoter methylation and protein expression of theDNAmismatch repair genes in epithelial ovarian cancer. Genomics 2014;104: 257-263.
78. Lee JH, Cragun D, Thompson Z et al. Association between IHC and MSI testing to identify mismatch repair-deficient patients with ovarian cancer. Genet Test Mol Biomarkers 2014;18:229-235.
79. Chui MH, Gilks CB, Cooper K et al. Identifying Lynch syndromein patients with ovarian carcinoma: the significance of tumor subtype. Adv Anat Pathol 2013;20:378-386.
80. Caliman LP, Tavares RL, Piedade JB et al. Evaluation of microsatellite instability in women with epithelial ovarian cancer. Oncol Lett 2012;4: 556-560.
81. Aysal A, Karnezis A, Medhi I et al. Ovarian endometrioid adenocarcinoma: Incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability. Am J Surg Pathol 2012;36:163-172.
82. Murphy MA, Wentzensen N. Frequency of mismatch repair deficiency in ovarian cancer: A systematic review. Int J Cancer 2011;129:1914-1922.
83. Pal T, Akbari MR, Sun P et al. Frequency of mutations in mismatch repair genes in a populationbased study of women with ovarian cancer. Br J Cancer 2012;107:1783-1790.
84. Kandoth C, Schultz N, Cherniack AD et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73.
85. McConechy MK, Ding J, Cheang MC et al. Useof mutation profiles to refine the classification of endometrial carcinomas. J Pathol 2012;228:20-30.
86. Thoury A, Descatoire V, Kotelevets L et al. Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability. Histol Histopathol 2014;29:1455-1466.
87. Ruiz I, Martín-Arruti M, Lopez-Lopez E et al. Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type. Gynecol Oncol 2014;134:20-23.
88. Egoavil C, Alenda C, Castillejo A et al. Prevalence of Lynch syndromeamongpatients with newly diagnosed endometrial cancers. PLoS One 2013;8: e79737.
89. Nelson GS, Pink A, Lee S et al. MMRdeficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome. Gynecol Oncol 2013;131:309-314.
90. Diaz-Padilla I, Romero N, Amir E et al. Mismatch repair status and clinical outcome in endometrial cancer: A systematic review and metaanalysis. Crit Rev Oncol Hematol 2013;88:154-167.
91. Stelloo E, Bosse T, Nout RA et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol 2015;28:836-844.
92. Peterson LM, Kipp BR, Halling KC et al. Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis. Int J Gynecol Pathol 2012; 31:195-205.
93. Steinbakk A, Malpica A, Slewa A et al. High frequency microsatellite instability has a prognostic value in endometrial endometrioid adenocarcinoma, but only in FIGO stage 1 cases. Anal Cell Pathol (Amst) 2010;33:245-255.
94. Mackay HJ, Gallinger S, Tsao MS et al. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group (NCIC CTG). Eur J Cancer 2010;46:1365-1373.
95. Taylor BS, Schultz N, Hieronymus H et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
96. Azzouzi AR, Catto JW, Rehman I et al. Clinically localised prostate cancer is microsatellite stable. BJU Int 2007;99:1031-1035.
97. Burger M, Denzinger S, Hammerschmied CG et al. Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer. J Mol Med(Berl) 2006;84:833-841.
98. Rohrbach H, Haas CJ, Baretton GB et al. Microsatellite instability and loss of heterozygosity in prostatic carcinomas: Comparison of primary tumors, and of corresponding recurrences after androgen-deprivation therapy and lymph-node metastases. Prostate 1999;40:20-27.
99. Hampel H, Frankel WL, Martin E et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352: 1851-1860.
100. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-618.
101. Guastadisegni C, ColafranceschiM, Ottini L et al. Microsatellite instability as a marker of prognosis and response to therapy: A metaanalysis of colorectal cancer survival data. Eur J Cancer 2010;46:2788-2798.
102. Moy AP, Shahid M, Ferrone CR et al. Microsatellite instability in gallbladder carcinoma. Virchows Arch 2015;466:393-402.
103. Sessa F, Furlan D, Zampatti C et al. Prognostic factors for ampullary adenocarcinomas: Tumor stage, tumor histology, tumor location, immunohistochemistry and microsatellite instability. Virchows Arch 2007;451:649-657.
104. Saetta AA, Gigelou F, Papanastasiou PI et al. High-level microsatellite instability is not involved in gallbladder carcinogenesis. Exp Mol Pathol 2006;80: 67-71.
105. Kidd M, Eick G, Shapiro MD et al. Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors. Cancer 2005;103:229-236.
106. An JY, Kim H, Cheong JH et al. Microsatellite instability in sporadic gastric cancer: Its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. Int J Cancer 2012;131:505-511.
107. Karahan B, Argon A, Yıldırım M et al. Relationship between MLH-1, MSH-2, PMS-2,MSH-6 expression and clinicopathological features in colorectal cancer. Int J Clin Exp Pathol 2015;8: 4044-4053.
108. Popat S, Houlston RS. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 2005;41: 2060-2070.
109. Gryfe R, Kim H, Hsieh ET et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl JMed 2000;342:69-77.
110. Tran B, Kopetz S, Tie J et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011;117: 4623-4632.
111. Goldstein J, Tran B, Ensor J et al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol 2014;25:1032-1038.
112. Koopman M, Kortman GA, Mekenkamp L et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009;100:266-273.
113. Wang L, Cunningham JM, Winters JL et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003;63:5209-5212.
114. Yamamoto H, Perez-Piteira J, Yoshida T et al. Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. Gastroenterology 1999;116:1348-1357.
115. Choi YY, Bae JM, An JY et al. Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis. J Surg Oncol 2014;110:129-135.
116. Falchetti M, Saieva C, Lupi R et al. Gastric cancer with high-level microsatellite instability: Target gene mutations, clinicopathologic features, and long-term survival. Hum Pathol 2008;39: 925-932.
117. Matsusaka K, Kaneda A, Nagae G et al. Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res 2011;71:7187-7197.
118. Wang K, Kan J, Yuen ST et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 2011;43:1219-1223.
119. Sunakawa Y, Lenz HJ.Molecular classification of gastric adenocarcinoma: Translating new insights from the cancer genome atlas research network. Curr Treat Options Oncol 2015;16:17.
120. Cristescu R, Lee J, Nebozhyn M et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. NatMed 2015;21:449-456.
121. Broaddus RR, Lynch HT, Chen LM et al. Pathologic features of endometrial carcinoma associated with HNPCC:Acomparison with sporadic endometrial carcinoma. Cancer 2006;106:87-94.
122. Nout RA, Bosse T, Creutzberg CL et al. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/ b-catenin and P53 pathway activation. Gynecol Oncol 2012;126:466-473.
123. Billingsley CC, Cohn DE, Mutch DG et al. Polymerase E (POLE) mutations in endometrial cancer: Clinical outcomes and implications for Lynch syndrome testing. Cancer 2015;121:386-394.
124. Pal T, Permuth-Wey J, Kumar A et al. Systematic review and meta-analysis of ovarian cancers: Estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology. Clin Cancer Res 2008;14:6847-6854.
125. Segev Y, Pal T, Rosen B et al. Risk factors for ovarian cancers with and without microsatellite instability. Int J Gynecol Cancer 2014;24:664-669.
126. Xiao X, Melton DW, Gourley C. Mismatch repair deficiency in ovarian cancer—Molecular characteristics and clinical implications. Gynecol Oncol 2014;132:506-512.
127. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Colorectal 2015. Available at https://www.nccn.org/professionals/ physician_gls/pdf/genetics_colon.pdf. Accessed April 2, 2016.
128. Buerki N, Gautier L, Kovac M et al. Evidence for breast cancer as an integral part of Lynch syndrome. Genes Chromosomes Cancer 2012;51:83-91.
129. Murata H, Khattar NH, Kang Y et al. Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability. Oncogene 2002;21: 5696-5703.
130. Raymond VM, Mukherjee B, Wang F et al. Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol 2013;31:1713-1718.
131. Ryan S, Jenkins MA, Win AK. Risk of prostate cancer in Lynch syndrome: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014;23:437-449.
132. Casorelli I, Bossa C, Bignami M. DNA damage and repair in human cancer: Molecular mechanisms and contribution to therapy-related leukemias. Int J Environ Res Public Health 2012;9:2636-2657.
133. Das-Gupta EP, Seedhouse CH, Russell NH. Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia. Br J Haematol 2001;114:307-312.
134. Carethers JM, Chauhan DP, Fink D et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999;117:123-131.
135. Hemminki A, Mecklin JP, Järvinen H et al. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000; 119:921-928.
136. Elsaleh H, Joseph D, Grieu F et al. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000;355:1745-1750.
137. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349: 247-257.
138. Klingbiel D, Saridaki Z, Roth AD et al. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: Results of the PETACC-3 trial. Ann Oncol 2015;26:126-132.
139. Kim GP, Colangelo LH, Wieand HS et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007;25:767-772.
140. Watanabe T, Wu TT, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344:1196-1206.
141. Collura A, Lagrange A, Svrcek M et al. Patients with colorectaltumorswith microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil-based chemotherapy. Gastroenterology 2014;146:401-411.
142. Jover R, Nguyen TP, Pérez-Carbonell L et al. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 2011;140:1174-1181.
143. Sargent DJ, Marsoni S, Monges G et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010;28: 3219-3226.
144. Webber EM, Kauffman TL, O’Connor E et al. Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FUbased chemotherapy. BMC Cancer 2015;15:156.
145. Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: Selecting optimal treatments for individual patients. J Clin Oncol 2015;33:1787-1796.
146. Kawakami H, Zaanan A, Sinicrope FA. Microsatellite instability testing and its role in the management of colorectal cancer. Curr Treat Options Oncol 2015;16:30.
147. Tougeron D, Mouillet G, Trouilloud I et al. Efficacy of adjuvant chemotherapy in colon cancer with microsatellite instability: A large multicenter AGEO study. J Natl Cancer Inst 2016;108:djv438.
148. Venderbosch S, Nagtegaal ID, Maughan TS et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: A pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014;20: 5322-5330.
149. Brooks GA, Enzinger PC, Fuchs CS. Adjuvant therapy for gastric cancer: Revisiting the past to clarify the future. J Clin Oncol 2012;30:2297-2299.
150. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-1964.
151. Ogino S, Nosho K, Irahara N et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG islandmethylator phenotype. Clin Cancer Res 2009;15:6412-6420.
152. Pagès F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl JMed 2005;353:2654-2666.
153. Kim H, Jen J, Vogelstein B et al. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. AmJ Pathol 1994;145:148-156.
154. Alexander J, Watanabe T, Wu TT et al. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 2001; 158:527-535.
155. Dolcetti R, Viel A, Doglioni C et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 1999;154:1805-1813.
156. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007;121:1-14.
157. Stewart TJ, Abrams SI. How tumours escape mass destruction. Oncogene 2008;27:5894-5903.
158. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 2015;27: 450-461.
159. Timmermann B, Kerick M, Roehr C et al. Somatic mutation profiles ofMSIandMSScolorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS One 2010;5:e15661.
160. Jung B, Doctolero RT, Tajima A et al. Loss of activin receptor type 2 protein expression in microsatellite unstable colon cancers. Gastroenterology 2004;126:654-659.
161. Markowitz S, Wang J, Myeroff L et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-1338.
162. Lal N, Beggs AD, Willcox BE et al. An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy. OncoImmunology 2015;4:e976052.
163. Boissière-Michot F, Lazennec G, Frugier H et al. Characterization of an adaptive immune response in microsatellite-instable colorectal cancer. OncoImmunology 2014;3:e29256.
164. Kaplan DH, Shankaran V, Dighe AS et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95:7556-7561.
165. Llosa NJ, Cruise M, Tam A et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015;5:43-51.
166. Mlecnik B, Bindea G, Angell HK et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 2016;44: 698-711.
167. Gatalica Z, Snyder C, Maney T et al. Programmedcell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev 2014;23:2965-2970.
168. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-264.
169. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331:1565-1570.
170. Kmieciak M, Payne KK, Wang XY et al. IFN-g Ra is a key determinant of CD81 T cell-mediated tumor elimination or tumor escape and relapse in FVB mouse. PLoS One 2013;8:e82544.
171. Hallermalm K, Seki K, De Geer A et al. Modulation of the tumor cell phenotype by IFNgammaresults in resistance of uvealmelanoma cells to granule-mediated lysis by cytotoxic lymphocytes. J Immunol 2008;180:3766-3774.
172. Taube JM, Klein A, Brahmer JR et al. Association of PD-1, PD-1 ligands,and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20: 5064-5074.
173. Le DT, Uram JN, Wang H et al. PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. J Clin Oncol 2016;34(suppl 4S): 195a.
174. Le DT, Uram JN,Wang H et al. Programmed death-1 blockade in mismatch repair deficient colorectal cancer. J Clin Oncol 2016;34(suppl): 103a.
175. Merck Sharp & Dohme Corp. Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177). NLM Identifier: NCT02563002. Available at https://clinicaltrials.gov/ct2/show/ NCT02563002. Accessed March 25, 2016.
176. Snyder A, Makarov V, Merghoub T et al. Geneticbasis forclinical responsetoCTLA-4blockadein melanoma. N Engl J Med 2014;371:2189-2199.
177. Rizvi NA, Hellmann MD, Snyder A et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-128.
178. Kandoth C, McLellan MD, Vandin F et al. Mutational landscape and significance across 12 major cancer types. Nature 2013;502:333-339.
179. Sato Y, Yoshizato T, Shiraishi Y et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 2013;45:860-867.
180. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803-1813.
181. Vogelstein B, Papadopoulos N, Velculescu VE et al. Cancer genome landscapes. Science 2013;339: 1546-1558.